Future oncology最新文献_第8页

The present and future of lung cancer screening: latest evidence. 肺癌筛查的现在和未来：最新证据。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1080/14796694.2025.2501516

Juan Gutiérrez Alliende, Ella A Kazerooni, Philip A J Crosbie, Xueqian Xie, Ankur Sharma, Joana Reis

引用次数: 0

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives. IDH突变胶质瘤管理的进展：IDH抑制剂，INDIGO试验的临床意义，以及未来的前景。

IF 3 4区医学

Future oncology Pub Date : 2025-05-27 DOI: 10.1080/14796694.2025.2511587

Christianne V Mojica, Katrina Mari E Gutierrez, Warren P Mason

引用次数: 0

Cemiplimab in the treatment of metastatic basal cell carcinoma. 西米单抗治疗转移性基底细胞癌。

IF 3 4区医学

Future oncology Pub Date : 2025-05-27 DOI: 10.1080/14796694.2025.2511568

Monika Bapna, Emily Ruiz

{"title":"Cemiplimab in the treatment of metastatic basal cell carcinoma.","authors":"Monika Bapna, Emily Ruiz","doi":"10.1080/14796694.2025.2511568","DOIUrl":"https://doi.org/10.1080/14796694.2025.2511568","url":null,"abstract":"Metastatic basal cell carcinoma (mBCC) is a rare but aggressive form of skin cancer that poses significant therapeutic challenges. Historically, systemic treatment options were limited, with hedgehog pathway inhibitors (HHIs) providing modest efficacy, but poor tolerability long term. This review explores cemiplimab, an immune checkpoint inhibitor targeting PD-1, as a novel therapeutic agent for mBCC. We examine its pharmacologic profile, clinical efficacy in clinical trials, safety and tolerability, and real-world performance. A comprehensive literature review was conducted using PubMed and clinical trial registries to assess cemiplimab's role in mBCC treatment, including its comparison to HHIs and potential in combination or neoadjuvant strategies. Cemiplimab has emerged as a transformative therapy for patients with mBCC who are intolerant to or have progressed on HHIs. Despite lower response rates compared to cutaneous squamous cell carcinoma, cemiplimab offers meaningful and durable disease control with a favorable safety profile and preservation of quality of life. Ongoing research into predictive biomarkers, neoadjuvant use, and combination regimens may further enhance its clinical utility.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer. EVOKE-01研究：sacituzumab govitecan与docetaxel在非小细胞肺癌患者中的应用

IF 3 4区医学

Future oncology Pub Date : 2025-05-15 DOI: 10.1080/14796694.2025.2489339

Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M Patel, Takayuki Takahama, Scott P Owen, Douglas M Reznick, Firas B Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino

引用次数: 0

Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients. pMMR或非msi - h转移性结直肠癌患者的生物标志物检测、治疗模式和结果

IF 3 4区医学

Future oncology Pub Date : 2025-05-15 DOI: 10.1080/14796694.2025.2504246

K Desai, M Amonkar, R Jain, G Patton, K Estenson, A Sartaj, D Cosgrove, S Sura

{"title":"Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients.","authors":"K Desai, M Amonkar, R Jain, G Patton, K Estenson, A Sartaj, D Cosgrove, S Sura","doi":"10.1080/14796694.2025.2504246","DOIUrl":"https://doi.org/10.1080/14796694.2025.2504246","url":null,"abstract":"Aim: To assess biomarker testing utilization, treatment patterns, and clinical outcomes in previously treated proficient mismatch repair deficient (pMMR) or non-microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) patients.Materials & methods: Using the iKnowMed electronic health record database, this study included pMMR/non-MSI-H adult mCRC patients previously treated with standard-of-care (SoC) chemotherapies between 1 January 2016 and 31 December 2021. Patients were censored for overall survival (OS) and real-world progression-free survival (rwPFS) at their last visit date or the end of study period, 31 August 2022.Results: MSI/MMR testing was conducted in 70.9% of mCRC patients. In 292 previously treated mCRC patients, 69.5% received SACT (regorafenib:14.8%, trifluridine+tipiracil (TAS-102):12.3%, other SACT:72.9%), 28.8% received BSC and 1.7% received no BSC/SACT. The most common other SACT included irinotecan- (37.4%) and oxaliplatin-based (14.8%) therapies. The most patients were tested for KRAS (89%) and BRAF (81%). Overall, the median (95% CI) OS and rwPFS was 7.4(5.8,8.8) and 3.5(3.2,4.3) months, respectively.Conclusions: Only 70.9% of mCRC patients received guideline-recommended MSI/MMR testing, indicating a need for improved testing rates. Additionally, only 27.1% of previously treated mCRC patients received SoC options (regorafenib/TAS-102). The real-world variability in treatment choices and a high rate of chemotherapy rechallenge in subsequent lines highlight an unmet need in this patient population.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of mTOR inhibitors combined with endocrine therapy versus that alone in breast cancer: a meta-analysis. mTOR抑制剂联合内分泌治疗与单独治疗乳腺癌的比较：荟萃分析。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-28 DOI: 10.1080/14796694.2025.2485022

Wei Zhang, Xinru Jia, Dandi Lou, Qingping Wu, Yici Yan, Feiyan Mao

{"title":"Comparison of mTOR inhibitors combined with endocrine therapy versus that alone in breast cancer: a meta-analysis.","authors":"Wei Zhang, Xinru Jia, Dandi Lou, Qingping Wu, Yici Yan, Feiyan Mao","doi":"10.1080/14796694.2025.2485022","DOIUrl":"10.1080/14796694.2025.2485022","url":null,"abstract":"Background: This meta-analysis aims to evaluate the efficacy and safety of rapamycin (mTOR) inhibitors with endocrine therapy versus endocrine therapy alone in treating advanced or metastatic estrogen receptor/progesterone receptor (ER/PR) + breast cancer.Methods: We conducted a comprehensive search in PubMed, Web of Science, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing mTOR inhibitors plus endocrine therapy with endocrine therapy alone up to September 2024.Results: This analysis included 10 RCTs comprising 3,337 patients. Relative to endocrine therapy alone, the combination of mTOR inhibitors and endocrine therapy significantly improved the clinical benefit rate (RR = 1.41, p < 0.001), overall response rate (RR = 1.40, p = 0.006), progression-free survival (PFS; HR = 0.67, p < 0.001), and overall survival (OS; HR = 0.86, p = 0.056), although the improvement in OS was not statistically significant. Subgroup analyses indicated a more pronounced PFS advantage in patients under 65 years of age (HR = 0.55, p = 0.013) and those who had previously received chemotherapy (HR = 0.51, p = 0.001). However, the incidence of adverse events was higher in the combination therapy group, notably stomatitis (p < 0.001), elevated aspartate aminotransferase/alanine aminotransferase (p = 0.04), and diarrhea (p = 0.01).Conclusions: The combination of mTOR inhibitors with endocrine therapy offers superior efficacy with manageable toxicities in patients with advanced or metastatic ER/PR+ breast cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1417-1427"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma. Tislelizumab用于治疗晚期食管鳞状细胞癌。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/14796694.2025.2495542

Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato

{"title":"Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.","authors":"Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato","doi":"10.1080/14796694.2025.2495542","DOIUrl":"10.1080/14796694.2025.2495542","url":null,"abstract":"Advanced esophageal squamous cell carcinoma (ESCC) patients had poor prognosis and few effective drugs based on the randomized controlled trials (RCTs). In such a circumstance, recent RCTs have shown the clinical efficacy of immune checkpoint inhibitors (ICIs) as first- or second-line treatment for advanced ESCC patients. Tislelizumab is one of the anti-Programmed-Death-1 (PD-1) antibodies; at first, tislelizumab monotherapy showed clinical efficacy as a second-line treatment for advanced ESCC patients based on the results of the RATIONALE-302 trial. Since then, tislelizumab plus doublet chemotherapy has shown superiority in overall survival compared to doublet chemotherapy for untreated advanced ESCC patients in the RATIONALE-306 trial. In this review, we share the overview of the development of tislelizumab and discuss the future perspectives on ICIs for advanced ESCC patients. In our opinion, tislelizumab plus doublet chemotherapy is one of the first-line standard treatments for advanced ESCC patients regardless of Programmed cell Death ligand 1 expression. Some other ICI-containing treatments showed clinical efficacy for untreated ESCC patients; we need further investigation to select these treatments appropriately.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1473-1481"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA. amivantamab-lazertinib一线治疗MARIPOSA先前未治疗的高风险egfr改变的非小细胞肺癌的简单语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI: 10.1080/14796694.2025.2487407

Enriqueta Felip, Byoung Chul Cho, Shun Lu, Mehmet Ali Nahit Şendur, Shirish M Gadgeel, Seema Sethi, Joshua M Bauml, Hidetoshi Hayashi

引用次数: 0

A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study. STARBOARD研究中encorafenib联合binimetinib和pembrolizumab治疗BRAF v600突变黑色素瘤的初步结果的简单语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-05-06 DOI: 10.1080/14796694.2025.2488226

Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina, Timothy Panella, Tibor Csőszi, Paola Gerletti, Mahgull Thakur, Anna Poll, Alessandra di Pietro, Dirk Schadendorf

引用次数: 0

Cost-effective shallow genome-wide sequencing for profiling plasma cfDNA signatures to enhance lung cancer detection. 低成本的浅基因组测序分析血浆cfDNA特征，以提高肺癌的检测。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-25 DOI: 10.1080/14796694.2025.2483154

Van Thien Chi Nguyen, Dac Ho Vo, Thi Trang Tran, Thanh Truong Tran, Thi Hue Hanh Nguyen, Truong Dang Huy Vo, Thi Tuong Vi Van, Thi Luyen Vu, Minh Quang Lam, Giang Thi Huong Nguyen, Trung Hieu Tran, Ngoc Tan Pham, Quang Thinh Trac, Trong Hieu Nguyen, Thi Van Phan, Thi Huyen Dao, Huu Tam Phuc Nguyen, Luu Hong Dang Nguyen, Duy Sinh Nguyen, Hung Sang Tang, Hoa Giang, Minh Duy Phan, Hoai-Nghia Nguyen, Le Son Tran

{"title":"Cost-effective shallow genome-wide sequencing for profiling plasma cfDNA signatures to enhance lung cancer detection.","authors":"Van Thien Chi Nguyen, Dac Ho Vo, Thi Trang Tran, Thanh Truong Tran, Thi Hue Hanh Nguyen, Truong Dang Huy Vo, Thi Tuong Vi Van, Thi Luyen Vu, Minh Quang Lam, Giang Thi Huong Nguyen, Trung Hieu Tran, Ngoc Tan Pham, Quang Thinh Trac, Trong Hieu Nguyen, Thi Van Phan, Thi Huyen Dao, Huu Tam Phuc Nguyen, Luu Hong Dang Nguyen, Duy Sinh Nguyen, Hung Sang Tang, Hoa Giang, Minh Duy Phan, Hoai-Nghia Nguyen, Le Son Tran","doi":"10.1080/14796694.2025.2483154","DOIUrl":"10.1080/14796694.2025.2483154","url":null,"abstract":"Background: Lung cancer (LC) screening via low-dose computed tomography (LDCT) faces challenges including high false-positive rates and low patient compliance. Circulating tumor DNA (ctDNA)-based tests offer a minimally invasive alternative but are limited by high costs and low sensitivity, particularly in early-stage detection. This study introduces a cost-effective, shallow genome-wide sequencing approach for LC detection by profiling multiple cell-free DNA (cfDNA) signatures.Methods: We developed a multimodal cfDNA assay with shallow sequencing coverage (0.5×) that integrates fragmentomic, nucleosome, end-motif, and copy number alteration analyses. A machine-learning model trained on a discovery cohort (99 LC patients, 168 healthy controls) and validated on an independent cohort (58 LC patients, 71 controls) demonstrated robust performance.Results: The ensemble model exhibited outstanding performance, achieving an AUC of 0.97 and a specificity of 92% in both the discovery and validation cohorts, with sensitivities of 94% and 90%, respectively. Notably, it outperformed hotspot mutation-based assays and the multi-cancer SPOT-MAS assay in sensitivity across all LC stages.Conclusions: This assay provides a cost-effective, accurate, and minimally invasive method for LC detection, addressing the limitations of current screening methods. It represents a promising complementary tool to improve early detection and patient outcomes in LC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1391-1402"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0